$0.10
(Market cap
$1,179 Mln
Revenue (TTM)
$77 Mln
P/E Ratio
--
P/B Ratio
24.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2.5
-
Debt to Equity
0.1
-
Book Value
$0.5
-
EPS
$-3.4
-
Face value
--
-
Shares outstanding
88,960,619
10 Years Aggregate
CFO
$-585.25 Mln
EBITDA
$-750.22 Mln
Net Profit
$-720.92 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Kura Oncology (KURA)
| 27.5 | 44.2 | 53.1 | 57.2 | 9.6 | -7.0 | 8.4 |
|
BSE Sensex*
| -10.0 | -3.5 | 2.6 | -5.6 | 5.0 | 5.5 | 10.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Kura Oncology (KURA)
| 19.3 | -39.2 | 15.9 | -11.4 | -57.1 | 137.5 | -2.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Kura Oncology (KURA)
|
13.3 | 1,178.7 | 77.2 | -296.8 | -382.9 | -266.7 | -- | 24.2 |
| 86.3 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 270.6 | 17,746.8 | 1,054.4 | 755.9 | 5.7 | -- | 20.9 | 10.5 | |
| 72.7 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 59.0 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 110.2 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 358.2 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 117.4 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 541.1 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 591.3 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 |
Shareholding Pattern
View DetailsAbout Kura Oncology (KURA)
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor;... Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California. Read more
-
Chairman, CEO & President
Dr. Troy Edward Wilson J.D., Ph.D.
-
Chairman, CEO & President
Dr. Troy Edward Wilson J.D., Ph.D.
-
Headquarters
San Diego, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Kura Oncology (KURA)
What is the current share price of Kura Oncology Inc (KURA) Today?
The share price of Kura Oncology Inc (KURA) is $13.25 (NASDAQ) as of 04-Sep-2026 16:05 EDT. Kura Oncology Inc (KURA) has given a return of 9.62% in the last 3 years.
What is the current PB & PE ratio of Kura Oncology Inc (KURA)?
Since, TTM earnings of Kura Oncology Inc (KURA) is negative, P/E ratio is not available.
The P/B ratio of Kura Oncology Inc (KURA) is 24.15 times as on 04-Sep-2026, a 353 premium to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-3.28 |
5.25 |
2024 |
-4.36 |
1.83 |
2023 |
-7.29 |
2.80 |
2022 |
-6.19 |
2.00 |
2021 |
-7.14 |
1.84 |
What is the 52 Week High and Low of Kura Oncology Inc (KURA)?
The 52-week high and low of Kura Oncology Inc (KURA) are Rs 13.90 and Rs 7.36 as of 07-Sep-2026.
What is the market cap of Kura Oncology Inc (KURA)?
Kura Oncology Inc (KURA) has a market capitalisation of $ 1,179 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Kura Oncology Inc (KURA)?
Before investing in Kura Oncology Inc (KURA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.